Regenxbio (RGNX) Retained Earnings (2014 - 2026)
Regenxbio (RGNX) posted quarterly Retained Earnings of -$687000.0 for Q4 2025, up 7.29% year-over-year from -$640335.8 in Q4 2024, and down 5.37% quarter-over-quarter from -$652000.0 in Q3 2025.
Regenxbio (RGNX) Retained Earnings (2014 - 2026) Analysis & Trends
Regenxbio's Retained Earnings history runs 12 years deep, the most recent figure standing at -$687000.0 for Q4 2025.
- In Q4 2025, Retained Earnings rose 7.29% year-over-year to -$687000.0; the TTM figure through Dec 2025 stood at -$687000.0 (up 7.29% YoY), while the FY2025 annual figure was -$687000.0, up 7.29% from the prior year.
- Retained Earnings for Q4 2025 stood at -$687000.0, down from -$652000.0 in the prior quarter.
- The five-year high for Retained Earnings was -$652000.0 in Q3 2025, with the low at -$996.9 million in Q2 2025.
- The 5-year median for Retained Earnings is -$389.2 million (2021), against an average of -$360.1 million.
- The sharpest annual moves came in 2021 and 2025: Retained Earnings plunged 53020.0% in 2021, then soared 99.93% in 2025.
- Regenxbio's Retained Earnings stood at -$2.6 million in 2021, then tumbled by 17087.74% to -$441.6 million in 2022, then tumbled by 59.67% to -$705.0 million in 2023, then soared by 99.89% to -$741000.0 in 2024, then increased by 7.29% to -$687000.0 in 2025.
- Business Quant data shows RGNX's Retained Earnings at -$687000.0 in Q4 2025, -$652000.0 in Q3 2025, and -$996.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Regenxbio | 583.35 Mn | 477.83 Mn | 106.98 Mn | -1.19 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.19 Bn |
| Dec 31, 2025 | -687,000.00 |
| Sep 30, 2025 | -652,000.00 |
| Jun 30, 2025 | -996.90 Mn |
| Mar 31, 2025 | -926.07 Mn |
| Dec 31, 2024 | -741,000.00 |
| Sep 30, 2024 | -880.96 Mn |
| Jun 30, 2024 | -821.37 Mn |
| Mar 31, 2024 | -3.23 Mn |
| Dec 31, 2023 | -705.05 Mn |
| Sep 30, 2023 | -642.20 Mn |
| Jun 30, 2023 | -10.10 Mn |
| Mar 31, 2023 | -508.20 Mn |
| Dec 31, 2022 | -441.55 Mn |
| Sep 30, 2022 | -381.60 Mn |
| Jun 30, 2022 | -14.76 Mn |
| Mar 31, 2022 | -11.95 Mn |
| Dec 31, 2021 | -2.57 Mn |
| Sep 30, 2021 | -455.26 Mn |
| Jun 30, 2021 | -396.90 Mn |